Patents by Inventor Kenneth Wiggall

Kenneth Wiggall has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10336711
    Abstract: The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: July 2, 2019
    Assignee: GlaxoSmithKline LLC
    Inventors: Duke M. Fitch, Antony N. Shaw, Kenneth Wiggall
  • Publication number: 20180305323
    Abstract: The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
    Type: Application
    Filed: June 29, 2018
    Publication date: October 25, 2018
    Inventors: Duke M. Fitch, Antony N. Shaw, Kenneth Wiggall
  • Patent number: 10035779
    Abstract: The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: July 31, 2018
    Assignee: GlaxoSmithKline, LLC
    Inventors: Duke M. Fitch, Antony N. Shaw, Kenneth Wiggall
  • Publication number: 20160297772
    Abstract: The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
    Type: Application
    Filed: June 20, 2016
    Publication date: October 13, 2016
    Inventors: Duke M. FITCH, Antony N. SHAW, Kenneth WIGGALL, Kevin DUFFY, Jian JIN, Ronggang LIU
  • Patent number: 9340529
    Abstract: This invention relates to the use of triazolone derivatives for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of triazolones in the treatment of cancer.
    Type: Grant
    Filed: November 4, 2013
    Date of Patent: May 17, 2016
    Assignee: GlaxoSmithKline LLC
    Inventors: Nicholas David Adams, Christopher Joseph Aquino, Amita M. Chaudhari, Jonathan Michael Ghergurovich, Terence John Kiesow, Cynthia Ann Parrish, Alexander Joseph Reif, Kenneth Wiggall
  • Publication number: 20150315157
    Abstract: The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
    Type: Application
    Filed: July 2, 2015
    Publication date: November 5, 2015
    Inventors: Duke M. Fitch, Antony N. Shaw, Kenneth Wiggall
  • Publication number: 20140336383
    Abstract: The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
    Type: Application
    Filed: July 18, 2014
    Publication date: November 13, 2014
    Inventors: Duke M. Fitch, Antony N. Shaw, Kenneth Wiggall
  • Patent number: 8815884
    Abstract: The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: August 26, 2014
    Assignee: GlaxoSmithKline LLC
    Inventors: Duke M. Fitch, Antony N. Shaw, Kenneth Wiggall
  • Patent number: 8802864
    Abstract: This invention relates to the use of triazolone derivatives of Formula (I) for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of triazolones in the treatment of cancer.
    Type: Grant
    Filed: February 22, 2011
    Date of Patent: August 12, 2014
    Assignee: GlaxoSmithKline LLC
    Inventors: Nicholas D. Adams, Christopher Joseph Aquino, Amita M. Chaudhari, Jonathan M. Ghergurovich, Terence John Kiesow, Cynthia A. Parrish, Alexander Joseph Reif, Kenneth Wiggall
  • Publication number: 20140100213
    Abstract: This invention relates to the use of triazolone derivatives for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of triazolones in the treatment of cancer.
    Type: Application
    Filed: November 4, 2013
    Publication date: April 10, 2014
    Applicant: GlaxoSmithKline LLC
    Inventors: Nicholas David Adams, Christopher Joseph Aquino, Amita M. Chaudhari, Jonathan Michael Chergurovich, Terence John Kiesow, Cynthia Ann Parrish, Alexander Joseph Reif, Kenneth Wiggall
  • Publication number: 20140024666
    Abstract: The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
    Type: Application
    Filed: September 13, 2013
    Publication date: January 23, 2014
    Applicant: GlaxoSmithKline LLC
    Inventors: Duke M. Fitch, Antony N. Shaw, Kenneth Wiggall
  • Publication number: 20130303551
    Abstract: This invention relates to the use of pyrimidinone derivatives for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of pyrimidinones in the treatment of cancer.
    Type: Application
    Filed: January 10, 2012
    Publication date: November 14, 2013
    Inventors: Nicholas D. Adams, Alexander Joseph Reif, Kenneth Wiggall
  • Patent number: 8557834
    Abstract: The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
    Type: Grant
    Filed: November 2, 2012
    Date of Patent: October 15, 2013
    Assignee: GlaxoSmithKline LLC
    Inventors: Duke M. Fitch, Antony N. Shaw, Kenneth Wiggall
  • Publication number: 20130237535
    Abstract: This invention relates to the use of spirocyclic piperidine derivatives for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of spirocyclic piperidines in the treatment of cancer.
    Type: Application
    Filed: November 7, 2011
    Publication date: September 12, 2013
    Inventors: Nicholas D. Adams, Amita M. Chaudhari, Terence John Kiesow, Cynthia Ann Parrish, Alexander Joseph Reif, Lance Howard Ridgers, Stanley J. Schmidt, Kenneth Wiggall
  • Publication number: 20130078213
    Abstract: Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
    Type: Application
    Filed: August 24, 2012
    Publication date: March 28, 2013
    Inventors: Kevin J. Duffy, Connie Erickson-Miller, Daniel F. Eppley, Julian Jenkins, Juan I. Luengo, Nannan Liu, Alan T. Price, Antony N. Shaw, Sophie Visonneau, Kenneth Wiggall
  • Publication number: 20120316151
    Abstract: This invention relates to the use of triazolone derivatives of Formula (I) for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of triazolones in the treatment of cancer.
    Type: Application
    Filed: February 22, 2011
    Publication date: December 13, 2012
    Inventors: Nicholas D. Adams, Christopher Joseph Aquino, Amita M. Chaudhari, Jonathan M. Ghergurovich, Terence John Kiesow, Cynthia A. Parrish, Alexander Joseph Reif, Kenneth Wiggall
  • Patent number: 8324208
    Abstract: The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
    Type: Grant
    Filed: June 22, 2007
    Date of Patent: December 4, 2012
    Assignee: GlaxoSmithKline LLC
    Inventors: Kevin J. Duffy, Duke M. Fitch, Jian Jin, Ronggang Liu, Antony N. Shaw, Kenneth Wiggall
  • Publication number: 20100113444
    Abstract: The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I), (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
    Type: Application
    Filed: June 22, 2007
    Publication date: May 6, 2010
    Inventors: Kevin J. Duffy, Duke M. Fitch, Jian Jin, Ronggang Liu, Antony N. Shaw, Kenneth Wiggall
  • Patent number: 7674887
    Abstract: Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
    Type: Grant
    Filed: June 18, 2008
    Date of Patent: March 9, 2010
    Assignee: GlaxoSmithKline LLC
    Inventors: Kevin J. Duffy, Juan I. Luengo, Antony N. Shaw, Kenneth Wiggall
  • Publication number: 20090203692
    Abstract: This invention relates to newly identified compounds for inhibiting hYAK3 proteins and methods for treating diseases associated with hYAK3 activity.
    Type: Application
    Filed: May 18, 2006
    Publication date: August 13, 2009
    Inventors: Kevin Duffy, Deping Chai, Mirela Colon, Duke M. Fitch, Sarah Rae King, Antony N. Shaw, Rosanna Tedesco, Kenneth Wiggall, Neil W. Johnson, Michael N. Zimmerman